Terns Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Terns Pharmaceuticals's earnings have been declining at an average annual rate of -21.5%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 19.7% per year.
Key information
-21.5%
Earnings growth rate
107.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 19.7% |
| Return on equity | -35.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Jan 12
We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Sep 29Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Jun 06Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Feb 21Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Oct 03Terns Pharmaceuticals: The Easy Money Has Been Made
Sep 20Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08
Aug 08Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?
Jun 14Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Mar 16We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate
Nov 24We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Aug 24Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study
Jun 14Revenue & Expenses BreakdownBeta
How Terns Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -90 | 39 | 63 |
| 30 Sep 23 | 0 | -85 | 39 | 57 |
| 30 Jun 23 | 0 | -72 | 25 | 54 |
| 31 Mar 23 | 0 | -68 | 24 | 49 |
| 31 Dec 22 | 0 | -60 | 22 | 40 |
| 30 Sep 22 | 1 | -59 | 22 | 38 |
| 30 Jun 22 | 1 | -54 | 21 | 33 |
| 31 Mar 22 | 1 | -51 | 21 | 31 |
| 31 Dec 21 | 1 | -50 | 20 | 31 |
| 30 Sep 21 | 0 | -35 | 15 | 30 |
| 30 Jun 21 | 0 | -35 | 14 | 28 |
| 31 Mar 21 | 0 | -34 | 11 | 30 |
| 31 Dec 20 | 0 | -29 | 9 | 28 |
| 30 Sep 20 | 0 | -40 | 10 | -7 |
| 31 Dec 19 | 0 | -69 | 9 | 27 |
Quality Earnings: TERN is currently unprofitable.
Growing Profit Margin: TERN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TERN is unprofitable, and losses have increased over the past 5 years at a rate of 21.5% per year.
Accelerating Growth: Unable to compare TERN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TERN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: TERN has a negative Return on Equity (-35.33%), as it is currently unprofitable.